attention over Thanks, Andrew. the the product of the strategy. very growth will for has diamide that diamides, mentioned of of view months. on which includes were market successful I our the earlier Day. current the in a Today, received supplemented be diamides last environment. products couple an This I'll showing forward-looking franchise resilience the you our have our Investor differentiated renewed more progress at growth give robust update plans by This a we
to market growing past years. We the partner we on finally, explore footprint; business, time have set, us for our X frame, including target the that owned delivered new of expanding Over base, segments. the have the expand diamides accelerating every our size registrations, this geographic expanding brand-new introducing formulations allow and we've patented the and
All future. franchise profitably to that of we these results should provide the can the confidence continue into grow
FMC's the in the Slide over data have Turning $XX basic at roughly some than time grown over was XX% diamides which which market. of smaller X% entire Rynaxypyr XX% frame. Insecticides valued grown on about ingredients. and active Cyazypyr for includes at make billion a X class, Diamides few per current the the insecticides have market, to up FMC's insecticide total XXXX. of other more year diamides
can phased market them XX% the class High-value compound insecticide take older being diamides a you diamides from to leading the market of growing gained by X% share chemistry in as some see, as And rate at every regulators. outperformed continues annual as result. by growth and share technologies such out other insecticides,
acquisition this Partner more a total Cyazypyr has our show cycle to element making the with we than XX% This of our formulated than of ingredient the these are of estimate Turning strategy. partners our technical of arrangements. our and of diamide are more up since assets management breakdown life sales XX% products total sales either active year, will we under up continue made roughly grown that Slide Cyazypyr trend sales to key sales. $X.X of FMC Rynaxapyr billion diamide XXXX. in rapidly sales. XX,
key have end partners through add Many We with these global with countries decade. and the more long-term in go the of future. in X agreements agreements various the XX potential the over local to of agreements supply companies
as do have not since and expand dilutive, crops X/X Moreover, partnership access our XXXX, for partner to we up sales. the segments not these model our revenue to margin branded of own market X/X diamide our serve. and remaining sales helped while commercial activities, roughly that from The are made our has we in came currently customers, to which the partners sales diamide refer
inventories, branded Branded sales the actively resulting We've we've outperform as their have lower continued of shown overall XXXX. our breakdown sales. sales In seen company. the geographic XXXX, also manage our partners to in of
our made we to This in to XX%. Branded total or and at America Asia Latin up Latin in introductions. XX% by products America XX% at better the at by driven more of respective other diamides sales expected America outperform sales regional perform followed XX%, EMEA branded than line regions Branded new with in North than sales year, expect are sales.
crops in required includes branded of partner to diversity products. potential we is our overall have as revenue, diamide access On reflects market the than numerous well sales. the breakdown countries XX sell right crops. The crop as and an which across This these dozens of products important the broad more as selling market is factor note of
Our various including, monolithic are product importantly, agronomic as newly formulations, education. and defendable selling, grower support patented branding, and such are a mechanisms, not single most through diamides value
diamides help Our over million support our strategy. growth unique from a precision in Arc branded Intelligence $XXX offering, now powerful of ag and Farm revenue defend tool our diamides, and
Turning to XX. Slide
can multiple You life components. has diamide that see the cycle strategic managing
at pillars I to the innovation wanted Day and today. start framing on IP color in more provide these pillars will Investor but We November,
FMC to diamides of This sales innovation significantly portfolio. segmentation At a have across the continued expanding new developing and patented through to Since relies FMC obtaining drive XX. XX which more new than instead brands increased dozens acquisition, on any growth. them resulted has in formulations and and reliance innovation XXXX. labels, acquiring across since in diversity diverse sales, new and formulation by Slide spread to existing future formulations late countries. single launching already registrations brands on partner were minimize grow acquisition, Turning has the segmented
evident 'XX This 'XX, of to in branded in of modestly products from We of in some declined the even benefits time Rynaxapyr the total increase the core from to innovation recent started have diamides frame. already though is same sales see diamides. the
of from developed corn new Star was Premio approval and Coragen acquired on another soy, pulses example MaX not provides primarily is Brazilian innovation formulation crops higher we that Brazilian MaX concentration insecticide of did authorities. Coragen patent-pending, one received and powered that by Coragen diamides. is insect for citrus Rynaxapyr control cereals. when that of and a in is example applications targeted canola, the exist technology priority
The patent high sucking and with Bifenthrin, with and Rynaxypyr both of pending a chewing broad differentiated dual Star provides control. has spectrum a combination performance for extremely of action, extended mode immediate and Premio formulation its insects.
FMC across and XXXX. products new less patented Contributions and patent the has accelerate from portfolio formulations developed over XX away pending make new differentiated or older in few of moving launched products. further in will technologies FMC's X are sales XX% the branded past countries diamide expected These new few years to next from years. up
and updated countries view X,XXX regulatory a show has over for and in time filed our of Slides of granted an state FMC pending over XX the diamides. patent patents XX patent and lines. XX
While our of we One reflect our since development to this have changed extend lines. these outlook, last and time can XXXX patent mixtures included inclusion slide we of we patented coverage granted additional some and to patent-pending last shared commentary have from formulations the is not that in once overall beyond addition version cases.
are Approvals registration product than and must legal speaking, a crop is centers issue holder entities after initiated of does registrations protection start patent and by can any into by received government Patents the only generic be regulated that the ones Generally patent not bearing commercialization. actions on registrations. validity. have different
in of not infringing enforce Moreover, to give judgments rights we change FMC's other our place. with companies will and FMC patents to countries, patent countries do judgments a in seller other in patents any product. do freedom X party as the illegal country operate continue patent nor these in valid view
companies protection data or rights have permission different to products includes legal comply do otherwise a and of advocacy not do or have notifying regulatory with we their in law. strategy, unknown addition applicable also or have produce regulatory our about impurities regulators not our enforcement that In to that strategy
This a approve of continues voluntarily or been declined to have canceled regulatory withdrawn has result successful efforts. other In companies instances, and registrations strategy. from Numerous our be have to a companies. such as authorities applications
Hopefully, we'll growth At innovation provide a leaders. understanding current diamides. this overview FMC's view by the comprehensive more state this has other of strategic and driven next the Day, of provided our franchise for Investor of of a phase
up wrap the we would. it not let Finally, that clearly out XXXX has or me how by broader thought industry turned saying
reflect taken we to the the and believe a firmly we run channel I standpoint. However, from channel will demand cost destocking actions is its have right happening current believe what
Branded Plant portfolio, our lay all of the out We to continued outlook an will shows rest products, term. to provide open and Health Investor can and our outperform plan both of products for of new Day look Diamides many investments. the benefit where line forward over Our seeing you at near the new which We questions. FMC's for growth now the our long we strategic and technology the
